In FRDA, CrCEST MRI may be a useful biomarker of muscle-group-specific decline in OXPHOS capacity that can be leveraged to track within-participant changes over time. Appropriate participant selection and further optimization of the exercise stimulus will enhance the utility of this technique.
Sunday, October 17, 2021
In vivo assessment of OXPHOS capacity using 3 T CrCEST MRI in Friedreich's ataxia
Schur GM, Dunn J, Nguyen S, Dedio A, Wade K, Tamaroff J, Mitta N, Wilson N, Reddy R, Lynch DR, McCormack SE.; J Neurol. 2021 Oct 15. doi: 10.1007/s00415-021-10821-1. Epub ahead of print. PMID: 34652504.
Subscribe to:
Posts (Atom)
